Thematic photoMartin FalbisonerCC BY-SA 3.0Resized, encoded as WebP; displayed with responsive cropping under the original licenceSEC EDGAR published this disclosure on 2026-09-21. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗accession0001701247-26-000013
acquired disposedD
codeS
direct or indirectD
form4
is derivativefalse
issuer nameEnliven Therapeutics, Inc.
labelOpen market sale
Source record & verificationDates, provenance and technical details
Context
links are based on the recorded entity typeRecorded payloadStructured source data
Recorded payload
JSON payload as stored after parsing{
"accession": "0001701247-26-000013",
"acquired_disposed": "D",
"code": "S",
"direct_or_indirect": "D",
"form": "4",
"is_derivative": false,
"issuer_name": "Enliven Therapeutics, Inc.",
"label": "Open market sale",
"person_name": "Collins Helen Louise",
"price": 50.0312,
"role": "CHIEF MEDICAL OFFICER",
"security": "Common Stock",
"shares": 2916,
"shares_owned_after": 27084,
"source_path": "edgar/data/1701247/0001701247-26-000013.txt",
"ticker": "ELVN",
"transaction_date": "2026-09-17",
"value": 145890.9792
}Evidence-based analysis
facts, provenance and explicit model coverageDescriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.